Prostaglandin E1 structure
|
Common Name | Prostaglandin E1 | ||
---|---|---|---|---|
CAS Number | 745-65-3 | Molecular Weight | 354.481 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 529.3±50.0 °C at 760 mmHg | |
Molecular Formula | C20H34O5 | Melting Point | 115-116 °C | |
MSDS | Chinese USA | Flash Point | 288.0±26.6 °C | |
Symbol |
GHS06, GHS08 |
Signal Word | Danger |
Use of Prostaglandin E1Prostaglandin E1 (PGE1) is a potent vasodilator and activates the prostaglandin E1 (EP) receptor. |
Name | prostaglandin E1 |
---|---|
Synonym | More Synonyms |
Description | Prostaglandin E1 (PGE1) is a potent vasodilator and activates the prostaglandin E1 (EP) receptor. |
---|---|
Related Catalog | |
Target |
Human Endogenous Metabolite |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 529.3±50.0 °C at 760 mmHg |
Melting Point | 115-116 °C |
Molecular Formula | C20H34O5 |
Molecular Weight | 354.481 |
Flash Point | 288.0±26.6 °C |
Exact Mass | 354.240631 |
PSA | 94.83000 |
LogP | 2.24 |
Vapour Pressure | 0.0±3.2 mmHg at 25°C |
Index of Refraction | 1.546 |
Storage condition | -20℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Symbol |
GHS06, GHS08 |
---|---|
Signal Word | Danger |
Hazard Statements | H301-H361 |
Precautionary Statements | P281-P301 + P310 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
Hazard Codes | Xn:Harmful |
Risk Phrases | R22 |
Safety Phrases | 36-26 |
RIDADR | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | GY4569800 |
Packaging Group | III |
Hazard Class | 6.1(b) |
HS Code | 29375000 |
Precursor 3 | |
---|---|
DownStream 0 |
HS Code | 29375000 |
---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Chem. Res. Toxicol. 23 , 171-83, (2010) Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental... |
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ... |
|
LX0702, a novel snake venom peptide derivative, inhibits thrombus formation via affecting the binding of fibrinogen with GPIIb/IIIa.
J. Pharmacol. Sci. 127 , 462-6, (2015) Based on the structure of AAP, a novel anti-thrombotic peptide from snake venom which we discovered in our previous study, more than 60 compounds were designed and synthesized. One of these termed as ... |
EINECS 212-017-2 |
ProstaglandinE1 |
Minprog |
Prostaglandine E |
PGE1 |
PegE1 |
Prostaglandin E1 |
Topiglan |
Palux |
Liple |
(1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid |
7-{(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl}heptanoic acid |
alprostadil |
(11a,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid |
(11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid |
ONO 1608 |
MFCD00077860 |
(11a,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic Acid |
PGEl |
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11α,13E,15S)- |
Caverject |
l-pge1 |